160 related articles for article (PubMed ID: 33178990)
21. Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model.
Erdoğar N; Iskit AB; Eroğlu H; Sargon MF; Mungan NA; Bilensoy E
J Nanosci Nanotechnol; 2015 Dec; 15(12):10156-64. PubMed ID: 26682462
[TBL] [Abstract][Full Text] [Related]
22. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
Boehm BE; Cornell JE; Wang H; Mukherjee N; Oppenheimer JS; Svatek RS
J Urol; 2017 Sep; 198(3):503-510. PubMed ID: 28286068
[TBL] [Abstract][Full Text] [Related]
24. Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer.
Liem EIML; Baard J; Cauberg ECC; Bus MTJ; de Bruin DM; Laguna Pes MP; de la Rosette JJMCH; de Reijke TM
Med Oncol; 2017 Sep; 34(10):172. PubMed ID: 28866819
[TBL] [Abstract][Full Text] [Related]
25. Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
D'Andrea D; Gontero P; Shariat SF; Soria F
Transl Androl Urol; 2019 Feb; 8(1):85-93. PubMed ID: 30976572
[TBL] [Abstract][Full Text] [Related]
26. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for bladder cancer.
Fuge O; Vasdev N; Allchorne P; Green JS
Res Rep Urol; 2015; 7():65-79. PubMed ID: 26000263
[TBL] [Abstract][Full Text] [Related]
28. Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer.
Bachir BG; Dragomir A; Aprikian AG; Tanguay S; Fairey A; Kulkarni GS; Breau RH; Black PC; Kassouf W
Cancer; 2014 Aug; 120(16):2424-31. PubMed ID: 24752448
[TBL] [Abstract][Full Text] [Related]
29. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
Huang Z; Liu H; Wang Y; Zhang C; Xu T
Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
[TBL] [Abstract][Full Text] [Related]
30. Does switching the bacillus Calmette-Guérin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
Urol Oncol; 2018 Jun; 36(6):306.e1-306.e8. PubMed ID: 29530465
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
Takeuchi A; Eto M; Tatsugami K; Shiota M; Yamada H; Kamiryo Y; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Takahashi R; Yokomizo A; Ohara N; Yoshikai Y
Int Immunopharmacol; 2016 Jun; 35():327-331. PubMed ID: 27093372
[TBL] [Abstract][Full Text] [Related]
32. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
[TBL] [Abstract][Full Text] [Related]
33. A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer.
Bunimovich-Mendrazitsky S; Claude Gluckman J; Chaskalovic J
J Theor Biol; 2011 May; 277(1):27-40. PubMed ID: 21334346
[TBL] [Abstract][Full Text] [Related]
34. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
[TBL] [Abstract][Full Text] [Related]
35. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
[TBL] [Abstract][Full Text] [Related]
36. Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis.
Mizushima T; Jiang G; Kawahara T; Li P; Han B; Inoue S; Ide H; Kato I; Jalalizadeh M; Miyagi E; Fukuda M; Reis LO; Miyamoto H
Mol Cancer Ther; 2020 Sep; 19(9):1930-1942. PubMed ID: 32737155
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
38. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
39. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin.
Hashizume A; Umemoto S; Yokose T; Nakamura Y; Yoshihara M; Shoji K; Wada S; Miyagi Y; Kishida T; Sasada T
Oncotarget; 2018 Sep; 9(75):34066-34078. PubMed ID: 30344922
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines.
Videira PA; Calais FM; Correia M; Ligeiro D; Crespo HJ; Calais F; Trindade H
Urology; 2009 Oct; 74(4):944-50. PubMed ID: 19428084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]